Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
5
71%
Ph phase_3
1
14%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
Phase 31 (14.3%)

Trials by Status

terminated229%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Phase II Trial GA101 Inbrutinib B CLL

NCT02666898
completedphase_1

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

NCT02315768
completedphase_2

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

NCT02401503
completedphase_2

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

NCT02445131
terminatedphase_2

GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma

NCT02495454
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02666898Phase 2

Phase II Trial GA101 Inbrutinib B CLL

Completed
NCT02315768Phase 1

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Completed
NCT02401503Phase 2

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Completed
NCT02445131Phase 2

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

Completed
NCT02495454Phase 2

GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma

Terminated
NCT02345863Phase 2

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Completed
NCT01659099Phase 3

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7